Back to top
more

Dr. Reddys Laboratories (RDY)

(Delayed Data from NYSE)

$78.47 USD

78.47
568,963

-1.97 (-2.45%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $78.47 0.00 (0.00%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes

Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.

FUJIFILM (FUJIY) Q1 Earnings Top Estimates, Revenues Drop Y/Y

FUJIFILM's (FUJIY) fiscal first-quarter results reflect coronavirus impact on the top line and operating income.

Dr. Reddy's Laboratories' Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Dr. Reddy's Laboratories.

Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y

Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.

Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease

Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.

Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.

Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY

The Zacks Analyst Blog Highlights: LLY, ABBV, NBIX and RDY

Manaswita Ghosh Dutta headshot

3 Stocks to Buy on New Drug Approvals by FDA

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

Dr. Reddy's Inks Deal With Gilead Sciences for Remdesivir

Dr. Reddy Laboratories (RDY) inks a deal with Gilead to register, manufacture and sell the latter's Remdesivir ??? a potential treatment for COVID-19 ??? in 127 countries including India.

Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

Are You Looking for a Top Momentum Pick? Why Doctor Reddy's (RDY) is a Great Choice

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

David Borun headshot

Bull of the Day: Dr. Reddy's Laboratories (RDY)

Generic pharmaceuticals are among the most naturally defensive industries during uncertain times

Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories

Zacks.com featured highlights include: Rocky Brands, FTI Consulting, Stamps.com, Sprouts Farmers Market and Dr. Reddy???s Laboratories

Nilanjan Banerjee headshot

Beat Coronavirus Blues With These 5 Low-Beta Stocks

A portfolio of low-beta stocks can protect your investments from the coronavirus-induced market volatility.

What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?

Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Will Dr. Reddy's Laboratories Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories

Amarin's Stock Plunges Following Unfavorable Patent Ruling

Amarin (AMRN) plans to appeal against unfavorable ruling from the District of Nevada in a patent litigation related to Vascepa and file an injunction against generic companies.

Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings (excluding impairment charge) increase year over year in the third quarter of fiscal 2020.

New Strong Sell Stocks for January 10th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for November 15th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for November 13th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for November 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today